(HealthDay News) — For high-risk patients undergoing percutaneous coronary intervention or transcatheter aortic valve replacement, furosemide with matched hydration via the RenalGuard system may reduce the incidence of contrast-induced acute kidney injury (CI-AKI), according to a meta-analysis published in JACC: Cardiovascular Interventions.
Alessandro Putzu, MD, from the Cardiocentro Ticino in Lugano, Switzerland, and colleagues conducted a meta-analysis to examine whether furosemide with matched hydration using the RenalGuard System correlated with reduced CI-AKI in patients undergoing interventional procedures. Four trials published from 2011 to 2016 with 698 patients undergoing percutaneous coronary procedures and transcatheter aortic valve replacement were included in the analysis.
The researchers found that, compared with control treatment, RenalGuard therapy correlated with significantly reduced incidence of CI-AKI (7.76% vs 21.43%; odds ratio, 0.31), as well as a reduced need for renal replacement therapy (0.58% vs 3.45%; odds ratio, 0.19). There were no major adverse events among patients undergoing RenalGuard therapy.
“Further independent high-quality randomized trials should elucidate the effectiveness and safety of this prophylactic intervention in interventional cardiology,” the authors write.
- Putzu A, Berto MB, Belletti A, et al. Prevention of Contrast-Induced Acute Kidney Injury by Furosemide With Matched Hydration in Patients Undergoing Interventional Procedures. JACC Cardiovasc Interv. February 2017. DOI: 10.1016/j.jcin.2016.11.006